(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 August 2012 (23.08.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/112576 A1

(51) International Patent Classification:
A61K 35/16 (2006.01) *C12N 5/0775* (2010.01)

(21) International Application Number:
PCT/US2012/025086

(22) International Filing Date:
14 February 2012 (14.02.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13/026,995 14 February 2011 (14.02.2011) US

(71) Applicant *(for all designated States except US)*: **ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC** [US/US]; 325 Paramount Drive, Raynham, Massachusetts 02767 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GOSIEWSKA, Anna** [US/US]; 39 Red Fox Court, Skillman, New Jersey 08558 (US). **HARMON, Alexander M.** [US/US]; 17 Hillside Drive, Clinton, New Jersey 08890 (US). **KIHM, Anthony J.** [US/US]; 7 Harrogate Circle, Princeton, New Jersey 08540 (US). **FANG, Carrie H.** [US/US]; 164 Oak Grove Road, Pittstown, New Jersey 08867 (US). **DHANARAJ, Sridevi** [US/US]; 3 Roderer Drive, Raritan, New Jersey 08869 (US).

(74) Agents: **HERBERT, Toni-Junell** et al.; Venable LLP, P.O. Box 34385, Washington, District of Columbia 20043-9998 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

[Continued on next page]

(54) **Title**: TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING UMBILICAL DERIVED CELLS




Fig. 1

(57) **Abstract**: This invention relates to methods of treating amyotrophic lateral sclerosis. In particular, the invention provides for methods of treating amyotrophic lateral sclerosis by administering umbilical cord tissue-derived cells, an effective amount of a substantially homogenous population of umbilical cord tissue-derived cells or a pharmaceutical composition comprising umbilical cord tissue-derived cells to a patient.

WO 2012/112576 A1

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*